«

»

Jennifer Doudna’s New Gene Editing Company Launches With A $20 Million Round To Develop Genetic Medicines

What if you had a tool to change the genetic instructions that cause disease? That's what San Francisco-based Scribe Therapeutics hopes to do with its next-generation platform for gene editing.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive